Brief: Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm Sublingual Film
02/12/2024 13:26
Dec 2 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS ANNOUNCES POSITIVE FDA FEEDBACK AND
REAFFIRMS NDA SUBMISSION GUIDANCE FOR ANAPHYLM™ (EPINEPHRINE)
SUBLINGUAL FILM
* AQUESTIVE THERAPEUTICS INC -CONFIRMS NO ADDITIONAL ADULT
CLINICAL TRIALS ARE NECESSARY PRIOR TO NDA SUBMISSION
* AQUESTIVE THERAPEUTICS INC -REAFFIRMS NEW DRUG APPLICATION
(NDA)
Q1 2025 SUBMISSION GUIDANCE
Source text: ID:nGNX6xwWj2
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million